Rigel Pharmaceuticals | RIGL - Przychody Ze Sprzedaży





Obroty Zmiana Data
Agenus USD 33.7M 500K 2026-03
Amgen USD 10.1B 1.48B 2026-06
Anika Therapeutics USD 30.62M 2.8M 2025-12
Arrowhead Research USD 75.23M 1.49M 2026-06
AstraZeneca USD 15.38B 90M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Celldex Therapeutics USD 22K 7K 2026-06
Daiichi Sankyo JPY 574.74B 12.26B 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Halozyme Therapeutics USD 481M 104M 2026-06
Heron Therapeutics USD 40.59M 2.38M 2025-12
Intrexon USD 717K 511K 2024-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Karyopharm Therapeutics USD 35.07M 987K 2026-03
Ligand Pharmaceuticals USD 83.7M 31.98M 2026-06
MacroGenics USD 20.8M 20.43M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Pfizer USD 15.03B 530M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sangamo BioSciences USD 356K 125K 2024-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Veracyte USD 150.32M 11.25M 2026-06